Human Rotavirus Vaccine Market Research Report-Forecast till 2027

Human rotavirus vaccine market information: by type (Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, others) by end users (hospitals & clinics, academic and research, others) - Forecast till 2027

ID: MRFR/Pharma/2827-HCR | February 2021 | Region: Global | 80 pages

Human rotavirus vaccine Market Scenario 

Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease. Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.

Rotavirus is a double-stranded RNA virus of the family Reoviridae and is transmitted through the faecal-oral route. It infects the cell lining of the small intestine and causes gastroenteritis. According to National Center for Biotechnology Information, rotavirus related diarrhoea was responsible for killing about 600,000 children in 2015, with more than 80% of all rotavirus-related deaths occurring in in South Asia and sub-Saharan Africa. Rotavirus-related deaths represent approximately 5% of all deaths in children younger than 5 years of age worldwide. Almost every child in the world is infected with rotavirus at least once by the age of five. The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs. The vaccines is responsible to prevent 15 to 34% of severe diarrhoea in the developing world and 37 to 96% of severe diarrhoea in the developed world. According to World Health Organization (WHO) in Mexico a decline of up to 50% in diarrhoeal deaths in children less than 5 years of age was attributed directly to the use of the vaccine.

The human rotavirus vaccine market drivers for rotavirus vaccine market are its safety profile including use in HIV/AIDS patients, growing number of immunity-compromised individuals, increasing geriatric population, growing population and live births etc. The market restraints are risks such as immune reaction, babies who have had intussusception, low healthcare expenditure in developing regions, cleanliness initiatives by NGOs and health awareness creation to eradicate the prevalence of this virus etc.

The global human rotavirus vaccine market is expected to reach US$ 12.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 11.2 % during the forecast period 2017-2023.

 Figure 1 Global Human rotavirus vaccine Market by End Users, 2016 (% market share) Global Human Rotavirus Vaccine Market

Human Rotavirus Vaccine Market Segments: 

The global Human rotavirus vaccine market has been segmented on the basis of type and end users.

Based on type, the human rotavirus vaccine market has been segmented as Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb and others.

Based on the end users, the human rotavirus vaccine market has been segmented as hospitals & clinics, academic and research and others.

Human Rotavirus Vaccine MarketRegional Analysis: 

The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global human rotavirus vaccine market. Also, concentration of major research companies and vaccine research sector in the developed countries of this region is adding fuel to the market growth. Europe is the second largest market in the world due to high income and healthcare penetration. Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period. Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Key Players 

Some of key players profiled in the report are 

  • Bharat Biotech

  • Merck & Co., Inc.

  • GlaxoSmithKline plc.

  • Multinational pharmaceutical drug company 

  • Others

The report for Global Human rotavirus vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions. 

Intended Audience

  • Global Human rotavirus vaccine treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities

Research Methodology:

Human Rotavirus Vaccine Market

Report Scope:
Report Attribute/Metric Details
  Market Size   2023: US$12.3 Billion
  CAGR   2017-2023: ~ 11.2%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2019
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bharat Biotech, Merck & Co., Inc., GlaxoSmithKline plc., Multinational pharmaceutical drug company and others.
  Key Market Opportunities

  • The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care
  • Europe is the second largest market in the world due to high income and healthcare penetration.
  •   Key Market Drivers

  • HIV/AIDS patients
  • Growing number of immunity-compromised individuals
  • Increasing geriatric population
  • Growing population and live births

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Human rotavirus vaccine market CAGR would be 11.2% during the forecast period.

    Human rotavirus vaccine market valuation would be USD 12.3 billion by 2023.

    The players involved in the human rotavirus vaccine market are Merck & Co., Inc., Multinational pharmaceutical drug company, GlaxoSmithKline plc., Bharat Biotech, and others.

    Human rotavirus vaccine market report includes academic and research, hospitals & clinics, and others.

    The types included in the human rotavirus vaccine market are RotaTeq, Rotavac, Rotarix, Lanzhou lamb, Rotavin-M1, and others.

    Table of contents
    1. Introduction

    1.1 Definition

    1.2 Scope of Study

    1.2.1 Research Objective

    1.2.2 Assumptions & Limitations Assumptions Limitations

    1.3 Market Structure

    2. Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research

    3. Market dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Macroeconomic Indicators

    4. Market factor analysis

    4.1 Porters Five Forces Model

    4.2 Bargaining Power of Suppliers

    4.3 Bargaining Power of Buyers

    4.4 Threat of New Entrants

    4.5 Threat of Substitutes

    4.6 Intensity of Rivalry

    5. Global Human Rotavirus Vaccine Market, by Type

    5.1 Rotarix

    5.2 Rotateq

    5.3 Rotavac

    5.4 Rotavin-M1

    5.5 Lanzhou Lamb

    5.6 Others

    6. Global Human Rotavirus Vaccine Market, by End Users

    6.1 Introduction

    6.2 Hospitals & Clinics

    6.3 Academic And Research

    6.4 Others

    7. Global Human Rotavirus Vaccine Market, by Region

    7.1 North America

    7.1.1 Introduction

    7.2 Europe

    7.2.1 Introduction

    7.3 Asia Pacific

    7.3.1 Introduction

    7.4 Middle East & Africa

    7.4.1 Introduction

    8. Competitive landscape

    8.1 Major Strategies Adopted by Market Players

    8.1.1 Strategic Partnership

    8.1.2 Merger & Acquisition

    9. Company profile

    9.1 Bharat Biotech

    9.1.1 Overview

    9.1.2 Product Overview

    9.1.3 Financials

    9.1.4 Key Developments

    9.2 Merck & Co., Inc.

    9.2.1 Overview

    9.2.2 Product Overview

    9.2.3 Financials

    9.2.4 Key Developments

    9.3 GlaxoSmithKline plc.

    9.3.1 Overview

    9.3.2 Product Overview

    9.3.3 Financials

    9.3.4 Key Development

    9.4 Sanofi

    9.4.1 Overview

    9.4.2 Product Overview

    9.4.3 Financials

    9.4.4 Key Development

    9.5 Others

    10. Conclusion

    10.1 Key Findings

    10.1.1 From CEO’s Viewpoint

    10.1.2 Unmet Needs of The Market

    10.2 Key Companies to Watch

    10.3 Prediction of Human Rotavirus Vaccine Industry

    11. Appendix